Terremoto Bio
Drug Discovery
$40.7Mlatest round · Venture round · Apr 2026 · 7 mo ago
3backers · RA Capital Management, EcoR1 Capital
2022founded
19stories in the press
Overview
By unleashing the power of covalent chemistry, we can deliver superior small molecule medicines with enhanced therapeutic benefit.
Funding and backers
Total raised
$40.7M
1 round on record
Latest round
$40.7M
Venture round · Apr 2026 · 7 mo ago
Backers
3
RA Capital Management, EcoR1 Capital
The money's age
Fresh money
7 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2026 | $40.7M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Terremoto Biosciences, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Charles BaumExecutive Officer, DirectorSEC Form D
James ChristensenExecutive Officer, DirectorSEC Form D
Grace LuExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Metanova Labs
Similar startupsby what they do, their industry and backers
Treeline Biosciences is a biotechnology company developing small-molecule medicines for cancer and immune diseases.
Metanova Labs is an AI drug discovery company building a new model for discovering and developing novel therapeutics. Through NOVA, its…
SYNthesis Med Chem is a global provider of small molecule drug discovery services and offers a unique support to drug discovery projects.
To find the right drug for the right target…. Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented…
We are bringing more disease-causing targets within the reach of small molecule therapeutics to transform care for patients with…
Novel therapies for metabolic inflammation and fibrosisThe Elgia team has discovered how metabolic stress drives inflammation and fibrosis…
Visa sponsorship
0
H-1B filings in 12 months
0
Open roles in United States
In the register as Terremoto Biosciences, Inc., South San Francisco, CA
Other sponsors in the same field
Genentech 
Exelixis 
Schrodinger 
Generate:Biomedicines
Alert me
US Department of Labor · latest filing Jan 23, 2025 · Visa details by country
Financials
Total raised
$40.7M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $40.7M | Details |
People
Charles Baum
Executive Officer, Director
James Christensen
Executive Officer, Director
Grace Lu
Executive Officer
Reid Huber
Director
Daniel O'Connell
Director
Peter Thompson
Director
Michael Goller
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
EcoR1 CapitalVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
RA Capital ManagementVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Terremoto Biosciences Appoints James Christensen, Ph.D., as Chief Executive Officer
.avia-section.av-b2nyyx-aeb7ac959a36e09287da187a00425313{ background-repeat:no-repeat; background-image:url(https://terremotobio.com/wp-content/uploads/article_header.jpg); background-position:50% 50%; background-attachment:scroll; } .flex_column.av-8us8q
Read more
Report
Terremoto Biosciences Closes $108 Million Series C Financing to Advance Selective AKT1-Inhibitors in Oncology and Hereditary Hemorrhagic Telangiectasia
Read more
Report
Report
Terremoto Biosciences Granted FDA Fast Track Designation for TER-2013, an AKT1-Selective Small Molecule Inhibitor for Breast Cancer
.avia-section.av-b2nyyx-aeb7ac959a36e09287da187a00425313{ background-repeat:no-repeat; background-image:url(https://terremotobio.com/wp-content/uploads/article_header.jpg); background-position:50% 50%; background-attachment:scroll; } .flex_column.av-8us8q
Read more
Report
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
South San Francisco
United States
HQ
South San Francisco